triazoles has been researched along with celecoxib in 18 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 4 (22.22) | 29.6817 |
| 2010's | 10 (55.56) | 24.3611 |
| 2020's | 4 (22.22) | 2.80 |
| Authors | Studies |
|---|---|
| Chow, LW; Toi, M; Wong, JL | 1 |
| Kammerer, S | 1 |
| Chow, LW; Guan, XY; Loo, WT; Toi, M; Zhu, L | 1 |
| Kohn, EC; Liotta, LA; Mehta, AI; Petricoin, EF; Winters, ME | 1 |
| Glück, S | 1 |
| Jiang, B; Li, MJ; Lu, T; Sun, NY; Wang, QJ; Wu, XM; Xu, JY; Zeng, Y; Zhang, YN | 1 |
| Chan, MS; Chanplakorn, N; Chanplakorn, P; Chow, LW; Ono, K; Sasano, H; Suzuki, T; Wang, L; Wing, L; Yiu, CC | 1 |
| Barañao, RI; Bilotas, MA; Meresman, GF; Olivares, CN; Ricci, AG | 1 |
| Chen, S; Pan, M; Tong, Y; Zhang, L; Zhang, X | 1 |
| Baryawno, N; Calero, R; Darabi, A; Dyberg, C; Einvik, C; Johnsen, JI; Kogner, P; Kool, M; Milosevic, J; Sandén, E; Siesjö, P; Sveinbjörnsson, B; Wickström, M | 1 |
| ElDemellawy, MA; Elzoghby, AO; Helmy, MW; Mostafa, SK; Sheweita, SA | 1 |
| Chen, X; Gu, L; Guo, P; Lv, M; Sun, X; Wang, B; Wang, S; Zhao, S | 1 |
| Chen, L; Li, D; Wu, X; Zhong, J | 1 |
| Ashour, HM; Fahmy, SM; Ibrahim, TM; Khalil, MA; Labouta, IM; Nassra, RA; Tageldin, GN | 1 |
| Abdellatif, KRA; Elshaier, YAMM; Fadaly, WAA; Hassanein, EHM | 1 |
| Bai, XQ; Cao, LT; Li, CS; Sun, SM; Zhang, TY; Zhao, DH | 1 |
| Baroni, ACM; Carvalho, DB; Carvalho, MG; Cassamale, TB; das Neves, AR; Duarte, RCF; Felipe, JL; Lourenço, LD; Toffoli-Kadri, MC | 1 |
| A A Abd El-Wahab, H; Abdel-Fattah, HA; E A Hassan, A; Ghanim, AM; Hamoud, MMS; Osman, NA; Rezq, S; Romero, DG | 1 |
1 review(s) available for triazoles and celecoxib
| Article | Year |
|---|---|
Exemestane as first-line therapy in postmenopausal women with recurrent or metastatic breast cancer.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Breast Neoplasms; Celecoxib; Estrogens; Female; Humans; Letrozole; Middle Aged; Multicenter Studies as Topic; Neoplasms, Hormone-Dependent; Nitriles; Postmenopause; Pyrazoles; Randomized Controlled Trials as Topic; Recurrence; Salvage Therapy; Sulfonamides; Tamoxifen; Triazoles | 2010 |
3 trial(s) available for triazoles and celecoxib
| Article | Year |
|---|---|
Celecoxib anti-aromatase neoadjuvant (CAAN) trial for locally advanced breast cancer: preliminary report.
Topics: Androstadienes; Antigens, Neoplasm; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Breast Neoplasms; Carcinoembryonic Antigen; Celecoxib; Enzyme Inhibitors; Female; Humans; Letrozole; Middle Aged; Neoadjuvant Therapy; Nitriles; Postmenopause; Pyrazoles; Sulfonamides; Treatment Outcome; Triazoles | 2003 |
Her2/neu expression predicts the response to antiaromatase neoadjuvant therapy in primary breast cancer: subgroup analysis from celecoxib antiaromatase neoadjuvant trial.
Topics: Aged; Aged, 80 and over; Androstadienes; Antineoplastic Agents; Aromatase Inhibitors; Breast Neoplasms; Celecoxib; Cyclooxygenase Inhibitors; Female; Gene Expression Regulation, Neoplastic; Humans; Immunohistochemistry; In Situ Hybridization, Fluorescence; Letrozole; Middle Aged; Neoadjuvant Therapy; Nitriles; Prognosis; Pyrazoles; Receptor, ErbB-2; Sulfonamides; Treatment Outcome; Triazoles | 2004 |
Increased 5α-reductase type 2 expression in human breast carcinoma following aromatase inhibitor therapy: the correlation with decreased tumor cell proliferation.
Topics: 17-Hydroxysteroid Dehydrogenases; 3-Oxo-5-alpha-Steroid 4-Dehydrogenase; Androstadienes; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Breast Neoplasms; Carcinoma, Ductal, Breast; Celecoxib; Cell Proliferation; Female; Humans; Immunohistochemistry; Letrozole; Neoadjuvant Therapy; Nitriles; Pyrazoles; Receptors, Androgen; Sulfonamides; Treatment Outcome; Triazoles | 2011 |
14 other study(ies) available for triazoles and celecoxib
| Article | Year |
|---|---|
[New prevention strategies against breast cancer and cervical carcinoma. What can you advice to your patients].
Topics: Adolescent; Adult; Age Factors; Anastrozole; Anticarcinogenic Agents; Breast Neoplasms; Celecoxib; Child; Double-Blind Method; Estrogen Antagonists; Female; Germany; Hormone Replacement Therapy; Humans; Hysterectomy; Life Style; Mammography; Menarche; Menopause; Middle Aged; Nitriles; Ovariectomy; Pregnancy; Pyrazoles; Raloxifene Hydrochloride; Randomized Controlled Trials as Topic; Risk Assessment; Risk Factors; Selective Estrogen Receptor Modulators; Smoking; Sulfonamides; Tamoxifen; Triazoles; Uterine Cervical Neoplasms | 2003 |
Supra-additive growth inhibition by a celecoxib analogue and carboxyamido-triazole is primarily mediated through apoptosis.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Calcium Channel Blockers; Celecoxib; Cell Cycle; Cell Line, Tumor; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibitors; Dinoprostone; Drug Screening Assays, Antitumor; Drug Synergism; ErbB Receptors; Humans; Indoles; Membrane Proteins; Prostaglandin-Endoperoxide Synthases; Pyrazoles; Signal Transduction; Sulfonamides; Transcriptional Activation; Triazoles | 2005 |
Design, synthesis, and biological evaluation of 1,5-diaryl-1,2,4-triazole derivatives as selective cyclooxygenase-2 inhibitors.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Carrageenan; Celecoxib; Cyclooxygenase 2 Inhibitors; Disease Models, Animal; Drug Design; Inflammation; Inhibitory Concentration 50; Male; Mice; Protein Binding; Pyrazoles; Rats; Rats, Sprague-Dawley; Sulfonamides; Triazoles | 2010 |
Anastrozole and celecoxib for endometriosis treatment, good to keep them apart?
Topics: Anastrozole; Animals; Aromatase Inhibitors; Celecoxib; Cyclooxygenase 2 Inhibitors; Drug Combinations; Drug Evaluation, Preclinical; Drug Incompatibility; Endometriosis; Female; Mesentery; Mice; Mice, Inbred BALB C; Nitriles; Peritoneal Diseases; Pyrazoles; Sulfonamides; Triazoles; Uterine Diseases | 2013 |
Arsenic sulfide combined with JQ1, chemotherapy agents, or celecoxib inhibit gastric and colon cancer cell growth.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Arsenicals; Azepines; Camptothecin; Celecoxib; Cell Line, Tumor; Cisplatin; Colonic Neoplasms; Drug Synergism; Gene Expression Regulation, Neoplastic; Humans; Irinotecan; p38 Mitogen-Activated Protein Kinases; Stomach Neoplasms; Sulfides; Triazoles; Tumor Suppressor Protein p53 | 2015 |
Wnt/β-catenin pathway regulates MGMT gene expression in cancer and inhibition of Wnt signalling prevents chemoresistance.
Topics: Animals; Antineoplastic Agents; Benzeneacetamides; beta Catenin; Brain Neoplasms; Camptothecin; Celecoxib; Cisplatin; Colorectal Neoplasms; Dacarbazine; DNA Modification Methylases; DNA Repair Enzymes; Doxorubicin; Drug Resistance, Neoplasm; Flow Cytometry; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Glioma; Glucose-6-Phosphate Isomerase; Heterocyclic Compounds, 3-Ring; Humans; Immunoblotting; Immunohistochemistry; Irinotecan; Medulloblastoma; Mice; Neoplasm Transplantation; Neoplasms; Neuroblastoma; Pyrans; Pyrazines; Pyridines; Real-Time Polymerase Chain Reaction; Sulfones; Temozolomide; Triazoles; Tumor Suppressor Proteins; Vincristine; Wnt Proteins; Wnt Signaling Pathway | 2015 |
Multi-Reservoir Phospholipid Shell Encapsulating Protamine Nanocapsules for Co-Delivery of Letrozole and Celecoxib in Breast Cancer Therapy.
Topics: Animals; Antineoplastic Agents; Breast Neoplasms; Celecoxib; Drug Carriers; Drug Combinations; Female; Humans; Letrozole; MCF-7 Cells; Mice, Inbred BALB C; Nanocapsules; Nitriles; Phospholipids; Protamines; Rats, Sprague-Dawley; Triazoles | 2017 |
Comparative pharmacokinetics study of anastrozole after single administration and combination with celecoxib.
Topics: Anastrozole; Animals; Antineoplastic Combined Chemotherapy Protocols; Celecoxib; Chromatography, Liquid; Cyclooxygenase 2 Inhibitors; Female; Limit of Detection; Nitriles; Rats, Sprague-Dawley; Reproducibility of Results; Tandem Mass Spectrometry; Triazoles | 2018 |
L161982 alleviates collagen-induced arthritis in mice by increasing Treg cells and down-regulating Interleukin-17 and monocyte-chemoattractant protein-1 levels.
Topics: Animals; Ankle Joint; Arthritis, Experimental; Arthritis, Rheumatoid; Celecoxib; Cell Differentiation; Cell Proliferation; Chemokine CCL2; Collagen Type II; Cyclooxygenase 2 Inhibitors; Dinoprostone; Down-Regulation; Female; Humans; Injections, Intraperitoneal; Interleukin-17; Mice; Mice, Inbred DBA; Receptors, Prostaglandin E, EP4 Subtype; Severity of Illness Index; Signal Transduction; T-Lymphocytes, Regulatory; Th17 Cells; Thiophenes; Triazoles | 2017 |
Synthesis, modeling and biological evaluation of some pyrazolo[3,4-d]pyrimidinones and pyrazolo[4,3-e][1,2,4]triazolo[4,3-a]pyrimidinones as anti-inflammatory agents.
Topics: Animals; Anti-Inflammatory Agents; Binding Sites; Celecoxib; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Diclofenac; Edema; Female; Granuloma; Inflammation; Molecular Docking Simulation; Molecular Structure; Pyrazoles; Pyrimidinones; Rats, Wistar; Structure-Activity Relationship; Triazoles | 2019 |
New 1,2,4-triazole/pyrazole hybrids linked to oxime moiety as nitric oxide donor celecoxib analogs: Synthesis, cyclooxygenase inhibition anti-inflammatory, ulcerogenicity, anti-proliferative activities, apoptosis, molecular modeling and nitric oxide relea
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Antineoplastic Agents; Apoptosis; Celecoxib; Cell Line, Tumor; Cell Proliferation; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Dose-Response Relationship, Drug; Drug Screening Assays, Antitumor; Humans; Male; Models, Molecular; Molecular Structure; Nitric Oxide; Oximes; PC-3 Cells; Pyrazoles; Rats; Rats, Wistar; Stomach Ulcer; Structure-Activity Relationship; Triazoles | 2020 |
New ursolic acid derivatives bearing 1,2,3-triazole moieties: design, synthesis and anti-inflammatory activity in vitro and in vivo.
Topics: Anti-Inflammatory Agents; Anti-Inflammatory Agents, Non-Steroidal; Celecoxib; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Dose-Response Relationship, Drug; Drug Design; Molecular Docking Simulation; Molecular Structure; Structure-Activity Relationship; Triazoles; Triterpenes; Ursolic Acid | 2022 |
Anti-inflammatory, ulcerogenic and platelet activation evaluation of novel 1,4-diaryl-1,2,3-triazole neolignan-celecoxib hybrids.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Anti-Ulcer Agents; Carrageenan; Celecoxib; Dose-Response Relationship, Drug; Edema; Lignans; Male; Mice; Molecular Structure; Peritonitis; Platelet Activation; Platelet Aggregation Inhibitors; Rats; Structure-Activity Relationship; Triazoles; Ulcer | 2022 |
Design and Synthesis of Novel 1,3,4-Oxadiazole and 1,2,4-Triazole Derivatives as Cyclooxygenase-2 Inhibitors with Anti-inflammatory and Antioxidant activity in LPS-stimulated RAW264.7 Macrophages.
Topics: Anti-Inflammatory Agents; Anti-Inflammatory Agents, Non-Steroidal; Antioxidants; Celecoxib; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Drug Design; Interleukin-6; Lipopolysaccharides; Macrophages; Molecular Docking Simulation; Nitric Oxide; Oxadiazoles; Reactive Oxygen Species; Structure-Activity Relationship; Triazoles | 2022 |